Clinical
RSSArticles
-
Brentuximab Neuropathy
Brentuximab, an antibody-drug conjugate for the treatment of lymphomas, carries a high risk of inflammatory sensory and motor neuropathies.
-
Risk of Autism After Prenatal Topiramate, Valproate, or Lamotrigine Exposure
The incidence of autism spectrum disorder was higher among children with prenatal exposure to the topiramate, valproate, and lamotrigine than the risk in the general population. However, after adjustment for indication of the medication (epilepsy) and other confounders, an increased risk was only observed in children with prenatal exposure to valproate.
-
Seizures in Adolescents: Motor or Nonmotor?
The rate at which motor vs. nonmotor seizures are recognized in adolescents is unknown. This retrospective analysis demonstrates a high rate of misrecognition of nonmotor seizures among adolescents presenting to an emergency department and frequent misrecognition of any nonmotor seizures in those presenting with a first-time motor seizure.
-
Novel Gene Therapy for Giant Axonal Neuropathy
The authors conducted a Phase I trial of a gene editing approach delivered by adeno-associated virus vector carrying a codon-optimized human giant axonal neuropathy transgene. The transgene targets anterior horn motor neuron bodies and sensory neurons in the dorsal root ganglia with the goal of repairing peripheral nerves and their axons. Each patient received a single intrathecal injection of the investigational agent. At one year, patients had less progression of disease compared to pretreatment intervals.
-
Ceftobiprole Medocaril Sodium for Injection (Zevtera)
The U.S. Food and Drug Administration has approved a new cephalosporin antibacterial for the treatment of three serious infections: bloodstream, skin and skin structure, and community-acquired pneumonia. Ceftobiprole is a fifth-generation cephalosporin with in vitro activity against gram-positive and gram-negative bacteria including multidrug resistant organisms. It will be distributed by Basilea Pharmaceutica International Ltd, Allschwil as Zevtera.
-
Another Step in the Journey to Combat Diagnostic Errors in Hospitalized Patients
Diagnostic errors in hospitalized patients who died or were transferred to the intensive care unit were common in this large retrospective, multicenter trial and frequently associated with patient harm. Problems with clinical assessment and ordering and interpreting tests were the most prevalent diagnostic process faults, with sepsis the diagnosis most associated with diagnostic error.
-
Increased Risk of Morbidity with Prolonged Use of PPIs Without an Indication Post-ICU
In previously critically ill adults, the use of a proton pump inhibitor without an indication for more than eight weeks increased morbidity and mortality.
-
The Burden of Clostridioides difficile Infection
This article outlines the clinical, social, and economic burden of Clostridioides difficile infection (CDI) in the United States and its shifting epidemiology.
-
Inappropriate Diagnosis of Pneumonia Is Common in Hospitalized Patients
A cohort study that included 48 hospitals in Michigan found that 12% of patients treated for community-acquired pneumonia were diagnosed inappropriately. Older age, dementia, and presenting with acute change in mental status increased the risk for misdiagnosis.
-
Navigating Hypoglycemia in Diabetes Care: Clinical Management Strategies and Glucagon Treatment Options
Hypoglycemia, defined as a blood glucose level less than 70 mg/dL, can be life-threatening, particularly with insulin therapy, and imposes a significant risk factor leading to severe morbidity and increased medical costs. As a preventable and potentially acute complication of diabetes management, providing proper patient education, identifying key risk factors, and tailoring treatment approaches are crucial for prevention.